(±)-Thalidomide
SIGMA/T144 - ≥98%, powder
Synonym: (±)
CAS Number: 50-35-1
Empirical Formula (Hill Notation): C13H10N2O4
Molecular Weight: 258.23
EC Number: 200-031-1
MDL Number: MFCD00153873
Linear Formula: C13H10N2O4
Product Type: Chemical
| assay | ≥98% |
| color | white |
| form | powder |
| InChI | 1S/C13H10N2O4/c16-10-6-5- |
| InChI key | UEJJHQNACJXSKW-UHFFFAOYSA |
| ligand | thalidomide |
| originator | Celgene |
| Quality Level | 200 ![]() |
| reaction suitability | reagent type: ligand |
| SMILES string | O=C1CCC(N2C(=O)c3ccccc3C2 |
| solubility | DMSO: 20 mg/mL, clear |
| Application: | Thalidomide has been used to study its neuropathological effects in mouse models of Alzheimer′s disease (AD). This study reported that long term administration of thalidomide causes beta-secretase inhibition and subsequently alleviates amyloid-like pathology. Furthermore, thalidomide has also been used to evaluate its teratogenic functions. Thalidomide was found to affect endodermal differentiation and neural development in differentiating human embryonic and induced pluripotent stem cells. |
| Biochem/physiol Actions: | (±)-Thalidomide selectively inhibits biosynthesis of tumor necrosis factor α (TNF-α). It also functions as an inhibitor of angiogenesis, an immunosuppressive agent, a sedative and a teratogen. Furthermore, thalidomide is known to exhibit antitumor functions in refractory multiple myeloma. |
| Features and Benefits: | This compound was developed by Celgene . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1 g in glass bottle |
| Packaging: | 100 mg in glass bottle |
| Preparation Note: | Thalidomide is soluble in DMSO at a concentration that is more than 20 mg/ml. It is insoluble in water and ethanol. |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H312 - H360D |
| Precautionary statements | P201 - P202 - P264 - P280 - P301 + P310 - P302 + P352 + P312 |
| Hazard Codes | T |
| Risk Statements | 61-22 |
| Safety Statements | 53-22-26-36/37/39-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Purity | ≥98% |
| UNSPSC | 12352111 |



